Food and Drug Regulatory Trends and Developments: Navigating Implications to the Year Ahead
Recording Available: Thursday, August 06, 2020
In 2016, the Food and Drug Administration (FDA) issued significant rules implementing changes to the nutrition labeling and serving size regulations on food packaging. The rules were initially set to take effect in July 2018, however, the FDA released a final rule extending the compliance dates to January 2020 for companies with more than $10 million revenue, and 2021 for manufacturers with lower revenue mark, respectively.
With the impending label changes, major implication for the food manufacturing industry are expected to arise. Thus, companies must be determined in adapting with regulatory updates and must ensure that their processes and systems are ready to be compliant with the new FDA regulations.
In this LIVE Webcast, a seasoned panel of thought leaders and professionals brought together by The Knowledge Group will provide the audience with an in-depth analysis of the food and drug regulatory trends. Speakers will also present important issues surrounding this significant topic and will provide helpful compliance tips to properly navigate their way in the legal landscape.
Key topics include:
- Food and Drug Administration – Trends and Updates
- Regulatory Changes
- Major Implications in the Food Industry
- Best Compliance Practices
Ropes & Gray LLP
Nelson Mullins Riley & Scarborough LLP
Who Should Attend:
- Food and Beverage Manufacturers
- Food Labeling Specialists
- Legal Advisors
- Compliance Officers
- Operations Managers
- Senior Management
Beth Weinman focuses her practice on FDA regulation and enforcement of laws governing pharmaceuticals, biologics, medical devices and dietary supplements. Beth provides counseling on issues related to off-label promotion, good manufacturing practices, good clinical practices, compounding, product recalls and withdrawals, False Claims Act (FCA) and Federal Food, Drug, and Cosmetic Act (FDCA) investigations.
Prior to joining Ropes & Gray, Beth spent nearly eight years as Associate Chief Counsel for Enforcement within FDA’s Office of Chief Counsel. In that role, she worked closely with FDA’s Office of Criminal Investigations, the Department of Justice and other government agencies to investigate and, when appropriate, prosecute alleged violations of the FDCA and related crimes under Title 18.
Before starting at FDA, Beth was an associate in the litigation department of a large New York law firm.
Beth Weinman focuses her practice on FDA regulation and enforcement of laws governing pharmaceuticals, biologics, medical devices and dietary supplements. …
Jennifer Mallory is a partner at Nelson Mullins Riley & Scarborough’s flagship office in Columbia, South Carolina where she focuses her practice in the areas of food, drug, and device law as well as clinical research, bioethics, and business and intellectual property litigation. She has served as a member of several boards including the Medical University of South Carolina Institutional Review Board, S.C. Bar Board of Governors, and the Rutland Ethics Alliance. Mallory holds graduate certificates in Clinical Research and the Law and in FDA Regulation and Liability—both from Seton Hall University School of Law. She earned her JD from Washington and Lee University School of Law and her BA from the University of South Carolina, cum laude.
Jennifer Mallory is a partner at Nelson Mullins Riley & Scarborough’s flagship office in Columbia, South Carolina where she focuses …
Print and review course materials
Method Of Presentation:
General knowledge of food and drug regulations
NY Category of CLE Credit:
Areas of Professional Practice
Unlock All The Knowledge and Credit You Need
Leading Provider of Online Continuing Education
It's As Easy as 1, 2, 3
UNLIMITED 1 Year Pass for only $199
About Ropes & Gray LLP
Ropes & Gray is a leading global law firm with 11 offices located around the world. Our Washington, D.C.-based FDA regulatory team includes seasoned lawyers knowledgeable in all areas of FDA regulation. The team’s varied backgrounds bring a breadth of perspectives to the practice which includes attorneys who have worked at the FDA, as in-house counsel at life sciences companies and as key policy advisors in Congress.
As part of our multidisciplinary life sciences group, our FDA regulatory team has a broad view of the commercial and regulatory forces affecting life sciences companies. In addition to traditional regulatory counseling and administrative litigation, we advise clients on corporate and transactional matters, government enforcement investigations, compliance program design and implementation, and FDA-related intellectual property analyses and litigation.
About Nelson Mullins Riley & Scarborough LLP
Nelson Mullins is an AmLaw 100 firm serving clients in more than 100 diversified practice areas. From a firm of one attorney in 1897 to 800+ attorneys, policy advisors, and professionals in 11 states and the District of Columbia today, we represent corporate and individual clients in a wide variety of areas, including: food/drug/device law, regulatory, healthcare, litigation, intellectual property, real estate capital markets, corporate, technology, banking, e-discovery, economic development, securities, finance, tax, estate planning, governmental relations, environmental, real estate, labor and employment, privacy and security, and white collar crime. Nelson Mullins’ clients range from Fortune 500 companies to private equity and venture funds and portfolio companies to emerging growth companies and start-ups.